

Deoxynivalenol induced inflammation and increased the adherence of entero-invasive *Escherichia coli* to intestinal epithelial cells via modulation of mucin and pro-inflammatory cytokine production

Murphy LY Wan^{1,2,3#*}, Vanessa Co Anna^{1#}, Paul C Turner⁴, Shah P Nagendra¹, Hani El-Nezami^{1,5*}

¹School of Biological Sciences, Faculty of Science, Kadoorie Biological Sciences Building, The University of Hong Kong, Pokfulam, Hong Kong;

²Department of Laboratory Medicine, Division of Microbiology, Immunology and Glycobiology, Lund University, 221 85 Lund, Sweden;

³School of Pharmacy and Biomedical Sciences, Faculty of Science and Health, University of Portsmouth, Portsmouth, United Kingdom

⁴Maryland Institute for Applied Environmental Health, School of Public Health, University of Maryland, College Park, Maryland, USA;

⁵Institute of Public Health and Clinical Nutrition, University of Eastern Finland, Kuopio, Finland.

[#]These authors contribute equally to the manuscript

Correspondence:

Dr Murphy Lam Yim Wan

School of Pharmacy and Biomedical Sciences, Faculty of Science and Health, University of Portsmouth, Portsmouth, United Kingdom

E-mail: murphy.wan@port.ac.uk

Dr. Hani El-Nezami

5S-13, Kadoorie Biological Sciences Building, The University of Hong Kong, Pokfulam Road, Hong Kong.

Email address: elnezami@hku.hk

33 **Abstract**

34 Deoxynivalenol (DON) is a mycotoxin that commonly occurs in crops. It was
 35 hypothesized that DON could trigger intestinal inflammation and increase the
 36 susceptibility of intestinal epithelial cells (IECs) to pathogen infection.
 37 Accordingly, the aim of this study was to investigate the effects of DON on
 38 intestinal susceptibility to pathogen infection. Semiconfluent Caco-2 cells were
 39 exposed to DON followed by acute entero-invasive *Escherichia coli* (EIEC)
 40 infection. The effects of DON and EIEC contamination on mucin, cytokines
 41 and related signal transduction pathways were examined as part of the local
 42 immune system. Caco-2 cells were able to generate a rapid immune response
 43 against DON with or without EIEC post-challenge. An increase in EIEC
 44 attachment to DON-exposed cells was observed, probably in part, mediated
 45 by modulation of secretory MUC5AC mucins and membrane bound MUC4
 46 and MUC17 mucins. Cells were also able to express and produce important
 47 mediators of inflammation, such as cytokines as a result of activation of toll-
 48 like receptors signalling cascades, modulation of nuclear factor κ -light chain-
 49 enhancer of activated B cells (NK- κ B) and/or mitogen-activated protein kinase
 50 (MAPK) pathways. These data indicate that DON may exert
 51 immunomodulatory effects on intestinal epithelial cells, which might thereby
 52 modify the susceptibility to bacterial infection.

53

54 Keywords: Bacterial infection; Cytokines; Deoxynivalenol; *Escherichia coli*;
 55 Mucins; Inflammatory responses

56

57

58

59 **1. Introduction**

60 The mycotoxin deoxynivalenol (DON) is secondary metabolite of
61 *Fusarium* fungi that frequently contaminate both human food and animal feed.
62 Human ingestion of DON contaminated grains can lead to different diseases,
63 including nausea, vomiting, diarrhoea, abdominal pain, headache, dizziness,
64 and fever (Sobrova et al. 2010).

65 DON has been known to be immunotoxic affecting cells of the immune
66 system and the gastrointestinal tract. DON induces “ribotoxic stress
67 response”, which results in the elevation of many pro-inflammatory genes
68 such as cyclooxygenase-2 (COX-2) and inducible nitric oxide synthase (iNOS)
69 as well as cytokines such as interleukin (IL)-6, IL-1 β and tumour necrosis
70 factor (TNF)- α (Moon et al. 2002, Moon et al. 2003, Pestka et al. 2004).

71 Foodborne pathogens can cause severe diseases including diarrhoea,
72 which are of considerable public health concerns. The most common
73 foodborne pathogens found to contaminate food include *Escherichia coli* (*E.*
74 *coli*) spp., *Clostridium perfringens*, *Listeria* spp. and *Salmonella enterica*
75 serotypes Enteritidis (Maciorowski et al. 2007). Among them, the most
76 important foodborne pathogen is *E. coli*. Enteroinvasive *E. coli* (EIEC) are
77 intracellular pathogens that invade colonic epithelial cells by first penetrating
78 the intestinal epithelium through microfold cells (M cells) to gain access to the
79 submucosa, producing a rather localized infection with subsequent
80 destruction of the underlying mucosa as a result of their active replication
81 (Croxen et al. 2013).

82 The mucus lining the intestinal epithelium provides an important
83 physicochemical barrier against ingested pathogens and toxins. It is

84 composed of a mixture of mucins, which are heavily glycosylated with O-
85 linked oligosaccharides and N-glycan chains linked to protein backbones.
86 There are two different structural and functional classes of mucins: secreted
87 gel-forming mucins (MUC2, MUC5AC, MUC5B, MUC6 and MUC19), and
88 transmembrane (membrane-bound) mucins (MUC1, MUC3A, MUC3B, MUC4,
89 MUC12, and MUC17). To initiate infection processes, bacteria need to find
90 ways to ensure their survival and colonization by first adhering to the intestinal
91 epithelium (Torres et al. 2003). Mucins can effectively impede the ability of
92 bacteria and viruses to invade and colonize the cells, prevent their spread
93 along the mucosal surfaces, and limit the amount of microbial-produced toxins
94 reaching mucosal cells (Liévin-Le Moal et al. 2006).

95 Previous studies from our laboratory and others have shown that DON
96 affected mucus production (Wan et al. 2014, Antonissen et al. 2015, Pinton et
97 al. 2015) and also cytokine production (Van De Walle et al. 2008, Van De
98 Walle et al. 2010, Wan et al. 2013). Bacterial pathogens such as *E. coli* could
99 also trigger host inflammatory responses by enhancing mucin expression that
100 protect bacterial intrusion to gut epithelium (Vieira et al. 2010, Xue et al. 2014),
101 and eliciting cytokine production (Jung et al. 1995, Eaves-Pyles et al. 2008). *E.*
102 *coli* can also be recognized by toll-like receptors (TLRs) (mainly TLR4), which
103 transduce signals to the nucleus, activate the transcription factor nuclear
104 factor κ -light chain-enhancer of activated B cells (NF- κ B) and initiate
105 inflammatory responses by producing inflammatory cytokines and
106 chemokines (Underhill et al. 2002, Dąbek et al. 2010). The intestinal tract is
107 the first barrier to ingested mycotoxins but also the first line of defence against
108 intestinal infection. Ingestion of some mycotoxins increases the susceptibility

109 to experimental or natural mucosal infections (Tai et al. 1988, Fukata et al.
110 1996, Stoev et al. 2000, Oswald et al. 2003, Vandenbroucke et al. 2011). So
111 far, there is only one study reporting that DON rendered the intestinal
112 epithelium more susceptible to *Salmonella Typhimurium* with a subsequent
113 potentiation of the inflammatory responses in the gut (Vandenbroucke et al.
114 2011).

115 Accordingly, it was hypothesized that DON could also increase the
116 susceptibility of intestinal epithelial cells (IECs) to an entero-invasive
117 pathogen infection and trigger intestinal inflammation. With DON and EIEC
118 infections being emerging issues with possible deleterious consequences for
119 both animal and human health and with the gastrointestinal tract being the
120 primary target, the aim of this study was to investigate the effects of low and
121 relevant concentrations of DON on intestinal susceptibility to acute EIEC
122 infection. Of the cell line models, the Caco-2 cell line, originally isolated from
123 human colon adenocarcinoma, in spite of lack of mucus production, is among
124 the most commonly used *in vitro* model of intestinal epithelium to study
125 bacterial adherence and invasion (Resta-Lenert et al. 2003, Ganan et al. 2010,
126 Resta-Lenert et al. 2011, Khodaii et al. 2017). Caco-2 cells were grown at
127 semi-confluence stages (2 to 3 days of culture) and used in this study, as they
128 were substantially more susceptible to infection than confluent cells.

129

130 **2. Materials and Methods**

131 **2.1 Chemicals and reagents**

132 Minimum Essential Medium (MEM), foetal bovine serum (FBS) and all other
133 cell culture reagents were obtained from Gibco-Life Technology (Eggenstein,

Germany). DON was obtained from Sigma Chemical Company (St. Louis, MO, USA) and was dissolved in dimethyl sulfoxide (DMSO) purchased from Sigma and stored at -20 °C before use. In addition, phosphate buffered saline (PBS), sodium biocarbonate, diethylpyrocarbonate (DEPC) and chloroform are purchased from Sigma. RNAisoPlus was purchased from Takara (Otsu, Japan). HiScriptTM RT SuperMix for qPCR and AceQ qPCR SYBR Green Master Mix were obtained from Vazyme Biotech Co. (Piscataway, NJ, USA).

141

2.2 Cell line and culture conditions

Caco-2 cells (passages 22-31) obtained from the ATCC (HTB-37) were maintained at 37 °C, 5% CO₂, 90% relative humidity in MEM+20% FBS. Routinely, cells were sub-cultured once a week using trypsin-EDTA (0.25%, 0.53 mM) and seeded at a density of 2x10⁶ cells per 180 cm² flask. All cells were screened for mycoplasma contamination with a MycoAlert mycoplasma detection kit (Lonza, Basel, Switzerland) prior to use.

149

2.3 Bacteria preparation

Enteroinvasive *Escherichia coli* (EIEC O29:NM) was from Prof Wei Chen from the State Key Laboratory of Food Science and Technology, Jiangnan University. EIEC were incubated overnight at 37 °C in Luria-Bertani (LB) broth until the stationary phase was reached. Subcultures of the overnight cultures in fresh medium were grown to a phase of exponential growth. Cells were centrifuged at 4,000 rpm (Beckman Coulter, Fullerton, CA; GS-6R centrifuge) for 5 min, wash with PBS twice and suspended in MEM+20% FBS to desired concentrations before adding to the epithelial cell layers.

159

160 2.4 Cell viability by CCK-8 assay

161 A CCK-8 colorimetric assay was performed to assess cell viability/cytotoxicity
 162 in response to different concentrations of DON without or with EIEC post-
 163 treatment. The CCK assay is a colorimetric assay based on the reduction of a
 164 tetrazolium salt, WST-8 (4-[3-(2-methoxy-4-nitrophenyl)-2-[4-nitrophenyl]-2H-
 165 5-tetrazolio]-1,3-benzene disulfonate sodium salt), to a water-soluble
 166 formazan by cellular NADH or NADPH (Ishiyama et al. 1997). The assay was
 167 performed following manufacturer's instruction (Dojindo, Kunamoto, Japan). In
 168 brief, cells were seeded at 2×10^4 cells/well in 96-well culture plates and
 169 allowed to grow for 3 days. At 3 days, cells were treated with different
 170 concentrations of DON (0, 2, 4, 8, 16 μ M) for 24 h. After 24 h incubation,
 171 Caco-2 cells were treated with medium containing exponentially grown EIEC
 172 bacteria at a multiplicity of infection (MOI) of 250:1 to the cells for 1 h. After
 173 that, cells were washed and incubated in medium with gentamicin (50 μ g/ml)
 174 for another 1 h. At the end of the incubation, CCK-8 solution (10 μ l) was
 175 added to each well, and the cells were incubated at 37 °C for 1 h. The colour
 176 intensity (absorbance) was determined using a microplate reader (model 550,
 177 BioRad) at 450 nm. Cell viability was expressed as the percentage of the
 178 mean value normalized to the control (untreated cells). For each treatment,
 179 the mean value was obtained from at least six wells.

180

181 2.5 Invasion and adhesion assay

182 The number of cells in each of the 24-well plate following DON treatment was
 183 first determined by trypan blue (Gibco) exclusion assay for calculation of MOI.

184 Invasion assay were performed using the gentamicin protection assay as
185 described previously (Boudeau et al. 1999). Briefly, Caoc-2 cells were seeded
186 in 24-well plates (1×10^5 cells) and cultured for 2 days. After 2 days, cells were
187 treated with different concentrations of DON (0, 8, 16 μ M) for 24 h. After 24 h
188 incubation, cells were treated with medium containing exponentially grown
189 EIEC at a MOI of 250:1 to the cells. After 1 h of incubation at 37°C, cells were
190 washed and incubated in medium with gentamicin (50 μ g/ml) (for cells
191 infected with invasive bacteria or uninfected controls) for another 1 h at 37°C.
192 The cells were then lysed with 0.1% Triton X-100 (Sigma) in deionized water.
193 Samples were diluted and plated onto LB agar plates to determine the colony
194 forming unit (CFU) recovered from the lysed cells. In control experiments,
195 gentamicin has no significant effect on any of the parameters measured.
196 Furthermore, no significant bacterial overgrowth was observed over the
197 duration of the experiment under all conditions tested. The percentage of
198 invading bacteria was expressed as $CFU_{(invading\ bacteria)}$ of infected cells divided
199 by $CFU_{(total\ bacteria)}$, normalized to the number of cells in each of the 24-well
200 plate following different concentrations of DON treatment.

201 To determine the total number of cell-associated bacteria
202 corresponding to adherent and intracellular bacteria, cells were lysed after 1 h
203 infection period, and the bacteria were quantified as described above. The
204 number of adhering bacteria was determined by subtracting the number of
205 invading bacteria from the total number of cell-associated bacteria. The
206 percentage of adhering bacteria was expressed as $CFU_{(adhering\ bacteria)}$ of
207 infected cells divided by $CFU_{(total\ bacteria)}$, normalized to the number of cells in
208 each of the 24-well plate following different concentrations of DON treatment.

209

210 2.6 Quantification of MUC protein expression

211 Expression of MUC protein by Caco-2 cells was studied using biotinylated
212 wheat germ agglutinin (WGA) (Vector Labs; Burlingame, CA, USA). Briefly,
213 Caco-2 cells were seeded onto 96-well plates and treated or not with DON
214 with or without EIEC infection as described above and were fixed with 4%
215 paraformaldehyde (PFA; Sigma) during 30 min at room temperature. After
216 fixation, cells were washed two times with 0.05% PBS-Tween 20 (PBS-Tw).
217 Cells were blocked for 1 h at room temperature in PBS supplemented with 2%
218 BSA and 0.1% Triton-X100. Biotinylated-conjugated WGA (1:10 000 dilution)
219 was then added to the wells for 1 h at room temperature followed by
220 incubation with avidin peroxidase (1:10 000 dilution) for another hour. Cells
221 were washed two times with PBS-Tw and 3,3',5,5'-tetramethylbenzidine
222 peroxidase (TMB) substrate (BioLegend; San Diego, CA, USA) was added.
223 Reaction was stopped with 2N sulphuric acid (Merck; Darmstadt, Germany)
224 and the optical density was read at 490 nm using the Multiskan microplate
225 spectrophotometer (ThermoFisher Scientific, Waltham, MA, USA). Relative
226 MUC protein expression was normalized to the number of cells in the well
227 following each treatment.

228

229 2.7 Quantitative polymerase chain reaction (qPCR) analysis

230 Cells were seeded and treated as above. After 1 h infection with EIEC, total
231 RNA was extracted using RNAisoTM Plus according to manufacturer's
232 instructions. The concentration of RNA was measured by using NanoDrop
233 ND-1000 Spectrophotometer (Nano-Drop Technologies, Wilmington, DE) with

234 purity ascertained by (A260/A280) of >1.8. RNA integrity was checked by
 235 running the RNA sample on ~1% agarose gel. Total RNA (500 ng) from each
 236 sample was converted into cDNA using HiScript™ RT SuperMix for qPCR
 237 according to the manufacturer's instructions. qPCR was performed to quantify
 238 the products of interest, cytokines and chemokines (IL-1β, IL-6, IL-8, TNF-α,
 239 MCP-1), mucins (MUC1, MUC3A, MUC4, MUC5AC, MUC5B, MUC17), Toll-
 240 like receptors (TLR-1, -2, -4, -5, -6) and related signalling molecules (MyD88,
 241 NF-κB). Assessment of glyceraldehyde-3-phosphate dehydrogenase
 242 (GAPDH) levels was also performed which served as an internal control for
 243 RNA integrity and loading. Human specific primers were described in Table 1.
 244 For analyses on a StepOnePlus™ Real-Time PCR system (Applied
 245 Biosystems, Foster City, CA, USA), 2 µl of 5X diluted cDNA was added to
 246 AceQ qPCR SYBR Green Master Mix, to obtain final primer concentrations of
 247 500 nM/primer in final volume of 10 µl. The sample was centrifuged briefly
 248 and run on the PCR machine using the default fast program (45 cycles of 95
 249 °C for 3 s, 60 °C for 30 s). To ensure the reliability of qPCR data, the
 250 amplicons are kept short (<250 bp) (Nolan et al. 2006). All PCR reactions
 251 were performed in duplicate. Negative controls, consisting in PCR mix
 252 components without cDNA was used for all primers. The relative product
 253 levels were quantified using the $2^{-\Delta\Delta CT}$ method as described previously (Livak
 254 et al. 2001).

255

256 2.8 Protein extraction, SDS-PAGE and immunoblotting

257 The cells, undergoing the same treatment as described for qPCR, were
 258 washed with PBS and extracted for total proteins (whole cell extracts). In brief,

100 µl of RIPA lysis buffer, supplemented with protease inhibitor cocktail (Sigma) and phosphatase inhibitors (Cell Signaling, Beverly, MA, USA) was used to extract total proteins from the cells. Protein concentration was determined by the DC protein assay (BioRad).

Proteins (10-50 µg) were loaded onto 10% sodium dodecyl sulfate polyacrylamide gel (BioRad), separated by electrophoresis (SDS-PAGE), and then blotted onto a polyvinylidene difluoride (PVDF) membrane (Millipore, Darmstadt, Germany). The membrane was blocked with 5% BSA in Tris-buffered saline (TBS) containing 0.05% (v/v) Tween 20 (TBST) buffer. Proteins were probed by immunoblotting with diluted rabbit primary antibodies from Cell Signaling (1:1000) for NF-κB p65 (#8242), p44/42 MAPK (Erk1/2) (#4695), phospho-p44/42 MAPK (Erk1/2) (#4370), JNK2 (#9258), phospho-SAPK/JNK (#4668), p38 MAPK (#8690), phospho-p38 MAPK (#4511) and GAPDH (ab181602; Abcam), followed by horseradish peroxidase (HRP)-conjugated anti-rabbit IgG (#170-6515, BioRad) secondary antibodies. The blots were developed using Clarity Western ECL blotting kit (BioRad) and chemiluminescence was detected with a digital imaging system (ChemiDoc XRS+ system with image lab software, BioRad). Quantification was performed by Image Lab software version 6.0 (Bio-Rad) by densitometric analysis (Schneider et al. 2012).

2.9 Statistical analyses

All assays were expressed as mean ± standard error of mean (SEM) for the number of separate experiments indicated. Data analyses were performed using the GraphPad PRISM 9.0 software (Graphpad Software Inc., San

284 Diego, CA). All data were first evaluated for normality with the Shapiro–Wilk
285 and Levene’s variance homogeneity test. For parametric data, one-way
286 analysis of variance (ANOVA) followed by Dunnet’s test against a control
287 group; for non-parametric data, one-way ANOVA with the Kruskal-Wallis test,
288 followed by the Dunn’s multiple comparisons test was used to identify
289 significant differences against a control group. Data are significantly different
290 at $p<0.05$, according to the post hoc ANOVA statistical analysis.

291

292 **3. Results**

293 **3.1 DON and EIEC lowered cell viability**

294 CCK assay was performed to investigate the effect of DON pre-
295 treatment on cell viability and to determine the concentrations of DON used in
296 subsequent experiments (Fig. 1A). DON resulted in a significant
297 concentration-dependent reduction in cell viability at 4, 8 and 16 μM ($p<0.05$).
298 DON at the concentrations of 8 and 16 μM were selected for the subsequent
299 experimental assays. The combined effect of DON and EIEC on cell viability
300 was also assessed. Addition of EIEC to cells pre-treated with 8 and 16 μM
301 DON significantly reduced cell viability compared to control (PBS) ($p<0.0001$),
302 but the reduction was not significantly different from cells treated with EIEC or
303 DON alone (Fig. 1B).

304

305 **3.2 DON increased EIEC adhesion but reduced invasion**

306 Since adhesion and invasion are both important processes in bacterial
307 pathogenesis, the effects of DON on EIEC adhesion and invasion were
308 assessed by a modified bacterial adherence assay and gentamicin protection

assay (Fig. 2). A preliminary bacterial invasion experiment was conducted in our laboratory by adding EIEC at MOI of 1:1, 2.5:1, 10:1, 25:1, 100:1, 250:1, 500:1, 1000:1 to the cells for 1 or 2 h. Results showed that EIEC at MOI of 250:1 for 1 h showed the highest invasion number to the cells from the colony counts (data not shown). Therefore, the MOI of 250:1 and 1 h of EIEC incubation were chosen for all the subsequent experiments. Pre-treatment with 8 and 16 μ M DON caused a significant increase in EIEC adherence ($p<0.05$) (Fig. 2A). However, cells pre-treated with DON reduced EIEC invasion significantly at ($p<0.05$) (Fig. 2B).

318

3.3 DON and EIEC contamination altered mucin gene expression and protein production

Mucin production is important in forming intestinal mucus, and acts as a physical barrier against bacterial infection. The effect of DON and EIEC exposure on mucin mRNA expression was determined by qPCR (Fig. 3) and protein production using the lectin wheat germ agglutinin (WGA) assay (Fig. 4).

Significant up-regulation of *MUC5AC* mRNA was found when cells were treated with all the treatment groups (Fig. 3A). Significant up-regulation of *MUC5B* mRNA was also observed when cells were treated with 16 μ M DON alone and with EIEC post-infection (Fig. 3B).

MUC1, *MUC4* and *MUC17* mRNA expression showed similar responses when treated with DON, where they experienced a gradual increase with increasing DON concentrations (Fig. 3C, E, F). For *MUC1*, in general, the mRNA expression level in cells with DON treatment alone

334 remained unchanged when compared to PBS control. DON pre-treatment
335 lowered *MUC3* mRNA expression level significantly ($p<0.05$). Addition of
336 EIEC did not affect *MUC3* mRNA expressions (Fig. 3D). When Caco-2 was
337 treated 16 μ M DON, *MUC4* and *MUC17* mRNA expression increased
338 significantly ($p<0.05$) compared to the PBS control. Addition of EIEC further
339 increased *MUC4* and *MUC17* mRNA expression ($p<0.01$) (Fig. 3E-F).

340 To investigate the effects of DON and EIEC treatment on the mucus
341 secretion, mucin-like glycoprotein secretion in cell lysates and those secreted
342 into culture supernatants were measured and analysed. Exposure to 8 and 16
343 μ M DON alone increased mucin protein production significantly ($p<0.05$).
344 Addition of EIEC, however, did not cause any significant change to the
345 amount of mucin protein produced compared to their pathogen-free
346 counterparts (Fig. 4).

347

348 3.4 DON and EIEC modulated pro-inflammatory cytokine and chemokine 349 gene expression

350 The effects of treating Caco-2 monoculture with DON and EIEC on pro-
351 inflammatory cytokine and chemokine mRNA expression were examined by
352 qPCR (Fig. 5). DON with and without EIEC post-treatment significantly
353 downregulated *IL1B* gene expression ($p<0.0001$) (Fig. 5A). Pre-treatment with
354 16 μ M DON upregulated *IL6* mRNA expression significantly ($p<0.05$); addition
355 of EIEC further increased the *IL6* mRNA ($p<0.001$) (Fig. 5B). In the absence
356 of DON, EIEC contamination alone significantly increased *IL8* and *TNFA*
357 mRNA expressions ($p<0.001$ and 0.05, respectively) (Fig. 5C and D). Pre-
358 treatment with all concentrations of DON lowered the *IL8* expression

significantly ($p < 0.0001$), but no significant change in *TNFA* was observed. Treatment with DON and EIEC both significantly down-regulated *CCL2* mRNA expression ($p < 0.001$), though it appeared DON's ability to modulate *CCL2* gene expression was greater than that of EIEC ($p < 0.0001$) (Fig. 5E).

363

3.5 DON and EIEC regulated TLRs and MyD88 gene expression

Pathogen associated molecular patterns (PAMPs) can be recognized by TLRs, which along with MyD88, can stimulate cytokines and chemokines production through NF- κ B activation. TLRs and MyD88 gene expression in response to DON and EIEC were assessed by qPCR (Fig 6). DON showed modest upregulation of *TLR1* gene at all concentrations tested; addition of EIEC to 16 μ M DON pre-treated cells, however, showed a remarkable increase in *TLR1* mRNA ($p < 0.001$) (Fig. 6A). For *TLR5*, the gene expression was downregulated significantly by DON at all concentrations in the absence and presence of EIEC ($p < 0.0001$) but no change was observed when cells were infected with EIEC alone (Fig. 6C). Due to the low expression of *TLR4* in Caco-2 cell line, its expression data for uninfected control and treatment groups were not shown. For *TLR2*, *TLR6* and *MYD88*, their gene expressions were not affected by the treatments significantly (Fig. 6B, D and E).

378

3.6 DON and EIEC tended to activate the NF- κ B p65 signalling pathway

p65 (RELA) and p50 (NF- κ B1) is the most commonly found heterodimer complex of NF- κ B, which participate in nuclear translocation and activation of NF- κ B to regulate gene expression and thus major cellular functions (Garg et al. 2013). Post-translational modifications of NF- κ B,

384 especially of the RELA subunit, further enhance the NF- κ B function as a
385 transcription factor (Huang et al. 2010). Therefore, in our study, qPCR and
386 western blot analyses were used to quantify *RELA* (or NF- κ B p65) levels as
387 an indicator for NF- κ B activation in response to DON and EIEC contamination
388 (Fig. 7). Treatment with DON alone resulted in an ascending trend in *RELA*
389 mRNA expression. Addition of EIEC further increased the mRNA expression
390 ($p < 0.01$) (Fig. 7A). Results obtained from western blot also revealed similar
391 patterns for NF- κ B protein expression. Up-regulation of NF- κ B p65 protein
392 expression was observed in cells infected with EIEC without and with DON
393 pre-treatment (Fig. 7B).

394

395 3.7 EIEC inhibited DON-induced MAPK signalling pathway activation

396 Previous studies have shown the involvement of MAPK signalling pathways in
397 DON-induced inflammation in intestinal cells (Van De Walle et al. 2008, Van
398 De Walle et al. 2010). In this study the three classical MAPK signalling
399 pathways, JNK, p38 MAPK and extracellular signal-regulated kinase (ERK)
400 were investigated in DON treated cells with and without EIEC post-infection
401 (Fig. 7C). Western blot data showed that DON treatment alone induced
402 significantly the phosphorylation of ERK and JNK, but not p38. However,
403 addition of EIEC to DON treated cells inhibited these MAPK signalling
404 pathways activation. EIEC alone also significantly inhibited p38 signalling
405 pathways but no change in p38 phosphorylation protein level was observed in
406 cells pre-treated with DON.

407

408 4. Discussion

409 The present study was the first to investigate the effects of low and
410 relevant concentrations of DON on intestinal susceptibility to acute (1-2 h)
411 EIEC infection. The effects of DON and EIEC contamination on mucin,
412 cytokines and related signal transduction pathways were examined in the
413 intestinal epithelial cells as part of the local immune system. The
414 concentrations of DON are in accordance with the levels probably
415 encountered in the gastrointestinal tract of animals or human tissues after
416 consumption of food or feed contaminated with DON (Sergent et al. 2006).
417 Assuming that DON ingested in one meal is diluted in 1 litre of gastrointestinal
418 fluid and is totally bio-accessible, the *in vitro* concentrations to be used in this
419 study correspond to food contamination ranging from 1.18 mg/kg to 4.72
420 mg/kg of DON (Van De Walle et al. 2008). The infection protocol (MOI and
421 EIEC treatment duration) was established based on a preliminary experiment
422 in our laboratory. Similar infection protocols were also adopted by other
423 investigators (Resta-Lenert et al. 2003, Ganan et al. 2010, Resta-Lenert et al.
424 2011).

425 Bacterial adherence to host cells is the initial crucial step towards
426 colonization and establishment of infection within the host (Torres et al. 2003).
427 In the present study, DON increased the adhesion of EIEC on intestinal
428 epithelial cells (IECs) but caused a reduced invasion into IECs. This may be
429 attributed to the induction of mucin gene and protein expression in IECs as
430 demonstrated in our study. Indeed, numerous studies have shown altered
431 mucin expression in chronic intestinal inflammatory diseases and cancer, both
432 in animal models and patient cohorts (Ho et al. 1993, Reis et al. 1999, Ho et
433 al. 2006, Longman et al. 2006, Moehle et al. 2006, Heazlewood et al. 2008,

434 Larsson et al. 2011). Both secretory and membrane-bound mucins are
 435 important constituents of the physicochemical barrier for the protection of the
 436 epithelial cell surface against undesirable harmful pathogens (Liévin-Le Moal
 437 et al. 2006). Over-expression and hyper-secretion of the secretory mucins, in
 438 particular, MUC5AC and MUC5B are two of the important characteristics of
 439 the inflammatory process in mucosa. Previous studies conducted by our
 440 laboratory indicate the modulation of biosynthesis of MUC5AC and MUC5B
 441 following exposure to DON in differentiated Caco-2 cells (Wan et al. 2014).
 442 However, no data are available concerning the effects of DON and EIEC on
 443 mucin production. Our finding demonstrated that MUC5AC and MUC5B
 444 mRNA was significantly increased upon DON and EIEC treatment. The rapid
 445 elevation of secretory mucin in responses to xenobiotics and bacterial
 446 infection is crucial for protecting intestine against pathogens and its
 447 metabolites (Snyder et al. 1987).

448 DON is known for its ability to activate signalling pathway and gene
 449 expression in goblet cells. Several studies indicated the potential involvement
 450 of mitogen-activated protein kinases (MAPKs). The initial binding of DON to
 451 ribosome leads to the activation of protein kinase R (PKR) that in turn causes
 452 the activation of the MAPKs and subsequently up-regulates human *MUC5AC*
 453 gene transcription. Less is known about the regulation of MUC5B expression.
 454 However, based on the possible common regulatory mechanism between
 455 MUC5AC and MUC5B (Moniaux et al. 2001), it is possible that *MUC5B* mRNA
 456 expression are regulated by MAPKs activation as well.

457 There is increasing evidence for the role of membrane-bound mucins in
 458 maintaining intestinal mucosal integrity. Among all identified membrane-bound

459 mucins, MUC3 and MUC17 are the membrane-bound mucins that are
 460 moderately expressed in the colon (Hattrup et al. 2008) and abundantly in
 461 both goblet cells and enterocytes of the small intestine (Ho et al. 1993, Kim et
 462 al. 2010). On the other hand, MUC1 and MUC4 are also expressed in normal
 463 intestinal tissues, but they are markedly upregulated in response to bacterial
 464 infection (McAuley et al. 2007, Lindén et al. 2008). In this study, we have
 465 shown a significant induction in *MUC1*, *MUC4* and *MUC17* but not *MUC3*
 466 mRNA in cells with DON and EIEC co-exposure. This was in agreement with
 467 a previous study that also demonstrated the protective role of MUC17 in
 468 protection of the intestinal mucosa against an EIEC strain (Resta-Lenert et al.
 469 2011). MUC17 contributes significantly to maintaining cell homeostasis and
 470 modulating chronic inflammatory responses by activating signalling pathways
 471 associated with inflammation and cancer. It was postulated that NF- κ B
 472 contributes, at least partly to the mucin regulation because all intestinally
 473 expressed mucin genes contain a potential or experimentally proven binding
 474 site for NF- κ B (Moehle et al. 2006). The NF- κ B regulatory pathway plays an
 475 important role in cell activation and production of diverse inflammatory
 476 mediators, including a variety of cytokines and chemokines (Hayden et al.
 477 2004). But of course, NF- κ B is not the only transcriptional regulator
 478 influencing mucin expression. Further studies are necessary to understand
 479 the mechanisms controlling the expression of mucin.

480 Besides acting as a physical barrier, IECs are able to express and
 481 produce important mediators of inflammation such as cytokines and
 482 chemokines and other signal molecules like TLRs that are important for host
 483 defence and bacterial recognition (e.g. lipopolysaccharides (LPS) from gram-

negative bacteria) (Arce et al. 2010). TLRs are expressed not only on immune cells but also non-immune cells such as epithelial cells. They can be rapidly induced in response to pathogens, cytokines and environmental stresses. TLR-1, -2, -4, -5 and -6 are expressed on the cell surface, which are implicated in the recognition of microbial membrane components for antimicrobial host defence (Akira et al. 2006). In this study, we showed that upon the treatment with DON and EIEC, the mRNA expression of TLRs was differentially modulated. DON without or with EIEC post-treatment induced *TLR1* gene expression but suppressed *TLR5* expression. *TLR2* and *TLR6*, however showed no significant up-regulation in our present study. This indicates that TLR-1, but not TLR-2 and -6 signalling, was involved in the induction of the early inflammatory responses by EIEC/DON in Caco-2 cells. In contrast, the downregulation of *TLR5* mRNA may function to attenuate excessive inflammatory responses due to DON and EIEC co-exposure. Surprisingly, very low or no expression of TLR-4 was present in any of treatments in Caco-2, and thus respond minimally to EIEC or DON. This is in contrast to other studies which showed induction of TLR expression in response to bacteria toxin (LPS from *Salmonella typhimurium*) in swine intestinal epithelial cell lines (IPEC-J2 and IPI-2I) (Arce et al. 2010), in bovine intestinal epithelial cells following *E. coli* 987P infection (Takanashi et al. 2013), as well as in IPEC-1 cells following enterotoxigenic *E. coli* (ETEC-O149) strain K88 treatment (Taranu et al. 2015). The decrease of TLR-4 and other TLRs (-2, -3, -6) were observed in porcine epithelial cells, macrophages, mesenteric lymph nodes and spleen of mice under the effects of mycotoxins (e.g., T-2 toxins, DON and ZEA) (Seebboth et al. 2012, Islam et al. 2013,

509 Taranu et al. 2015). All these results indicate that differential regulation of TLR
510 gene expression may contribute to inflammatory immune response against
511 bacterial infection in intestinal epithelial cells. However, EIEC treatment for 1 h
512 after DON treatment did not result in more changes in most of the TLRs
513 expression in the present study, implying DON is the major contributing factor
514 for the immune responses.

515 MyD88 is one of the most important adaptor molecules for
516 inflammatory signalling pathways. MyD88 mediates the activation of TLRs
517 and IL-1R and leads to the production of proinflammatory cytokines through
518 the activation of NF- κ B and MAPK signalling pathways (Akira et al. 2006).
519 Here we showed that *RELA* but not *MYD88* mRNA was significantly increased
520 in cells after DON with or without post-challenge with EIEC, in comparison to
521 the unchallenged cells, indicating that NF- κ B instead of MyD88 played a more
522 important role in regulating the inflammatory responses induced by DON and
523 EIEC. NF- κ B transcription factor plays a critical role in regulation of immune,
524 inflammatory and acute phase responses and is also implicated in the control
525 of cell proliferation and programmed cell death (Aggarwal et al. 2004). NF- κ B
526 is harmful to the host when excessively or improperly activated. The ability of
527 DON to influence NF- κ B activation has been extensively reported (Van De
528 Walle et al. 2008, Krishnaswamy et al. 2010, Kalaiselvi et al. 2013, Del Regno
529 et al. 2015, Adesso et al. 2017). In this study, we reported that DON
530 increased NF- κ B activation during inflammation. EIEC treatment for 1 h after
531 DON treatment caused a higher up-regulation of *RELA* mRNA and NF- κ B
532 protein. It is evident that activation of NF- κ B is followed by a series of events,
533 leading to the activation of signalling pathways, including MAPKs that are

crucial for regulating inflammation and producing inflammatory factors (Van De Walle et al. 2008, Van De Walle et al. 2010). Activation of these signalling cascades could lead to the production of pro-inflammatory cytokines. In the present work, we found that EIEC alone induced the mRNA expression of *IL8* and *TNFA*. Derangement of cytokine production by bacterial infection can lead to chronic inflammatory conditions (Karin et al. 2006). However, it is surprising to show that DON treatment significantly downregulated the mRNA expression of *IL1B*, *IL8* and *TNFA*. This result is in agreement with a previous report by Ghareeb *et al.*, which found that in broiler chickens, chronic administration of DON for 5 weeks resulted in significant down-regulation of certain cytokines, such as *IFNG* and *IL1B* mRNA in jejunal tissues (Ghareeb et al. 2013). Similar suppression of splenic *IFNG* and *IL1B* mRNA was also observed in another study in pigs following DON exposure (Cheng et al. 2006). DON is known to either suppress or stimulate immunological responses, depending on the dose, time and duration of exposure (Ghareeb et al. 2013). In this context, it becomes evident that DON has a modulating effect on the innate immune response. DON could modify the gene expression of cytokines, and thus may affect the susceptibility of human and animals to disease. In spite of the lack of quantifying the levels of proteins that are actually translated from the observed mRNA transcripts, this study is the first to present significant modulation of different pro-inflammatory cytokine mRNA expression in IECs and this might merit further investigation of the mechanisms in relation to the functional relevance of mRNA expression such as by determining the protein levels of the selected pro-inflammatory

558 cytokines by utilizing the quantitative sandwich enzyme immunoassay
559 (ELISA).

560 Moreover, to determine whether MAPK signalling pathways were
561 involved in the immune responses in cells upon DON and EIEC treatment, the
562 three MAPKs (JNK, p38 MAPK and ERK) were investigated. Consistent with
563 other previous studies, DON induced phosphorylation of JNK and ERK
564 proteins. Addition of EIEC to DON-pre-treated cells, however, suppressed
565 DON-induced phosphorylation of JNK and ERK. DON alone did not induce
566 p38 MAPK phosphorylation but EIEC alone inhibited the p38 MAPK signalling
567 pathway. Although it is evident that MAPK plays an important role in immune
568 responses to *E. coli* infection (Wang et al. 2007, Zhuang et al. 2017), its role
569 in the adherence and internalization of bacteria into epithelial cells was
570 unclear. It is postulated that such deactivation of MAPK pathways may
571 counteract the adhesion and invasion of bacteria into the cells, which are the
572 major contributing factors to intestinal infection and inflammation (Liu et al.
573 2012).

574 In conclusion, the above observations provide a context for the present
575 study, suggesting that exposure to DON could be a predisposing factor to
576 infectious disease. IECs are able to generate a rapid immune response
577 against DON and EIEC contaminants when they act alone or in combination.
578 The results also suggested the potential involvement in secretory MUC5AC
579 mucins and membrane bound MUC4 and MUC17 mucins in modifying the
580 attachment and invasion of EIEC and thus affecting the susceptibility to EIEC
581 infection. IECs are able to express and produce important mediators of
582 inflammation such as cytokines and other signal molecules like TLRs that are

important for host defence and bacterial recognition. The augmented mucin production and inflammatory stimulation might be a consequence of activation of NF- κ B signalling pathway. DON exposure also activated the MAPK signalling molecules, including ERK and JNK through phosphorylation. However, addition of EIEC to DON pre-treated cells inhibited MAPK signalling pathway which might help protecting intestinal epithelial cells from further damages caused by bacterial infection. A summary of the mechanisms of host defence responses against DON and EIEC co-exposure was depicted in Fig. 8. Nevertheless, further studies are necessary to examine different bacterial infection scenarios and to identify the complex mechanism(s) by which this mycotoxin acts on the intestinal tract to modulate invasion and colonization by opportunistic pathogens by using molecular approaches, such as high-throughput mRNA sequencing and proteomics. Epidemiological studies are also needed to assess the extent to which DON are involved in the development of infectious diseases in humans.

598

599 **Competing interests**

600 The authors declare no competing interests.

601

602 Figure Legends

603 Fig. 1. Effects of DON without or with EIEC post-infection on cell viability. (A)
 604 Preliminary screening of DON concentrations for subsequent experiments.
 605 Cell viability data of caco-2 cells treated with different concentrations of DON
 606 (0, 2, 4, 8 and 16 μ M) for 24 hours. (B) Cell viability data of Caco-2 cells
 607 treated with DON (8 and 16 μ M) for 24 hours without or with EIEC bacteria
 608 post-treatment at a multiplicity of infection (MOI) of 250:1 to the cells for 1 h.
 609 Control received appropriate carriers. Results were shown as mean $\pm$ SEM,
 610 which are from four independent experiments performed in six replicates. *, **,
 611 ***, *** $p < 0.05$, 0.01, 0.001 and 0.0001 compared to PBS control. One-way
 612 ANOVA post Dunnet's test.

613
 614 Fig. 2. Effects of 24 h of DON incubation on Caco-2 cells without or with EIEC
 615 post-infection (1 h) on bacterial adhesion and invasion. The percentage of (A)
 616 adhering and (B) invaded bacteria were calculated as described in Materials
 617 and Methods. Results were shown as mean of $\pm$ SEM, which are from four
 618 separate experiments performed in duplicates. *, ** $p < 0.05$ and 0.01
 619 compared to PBS control. One-way ANOVA post Dunn's test.

620
 621 Fig. 3. Effects of 24 h DON incubation without or with EIEC post-infection (1
 622 h) on mucin (*MUC*) gene expression. (A-B) Secretory *MUC5AC* and *MUC5B*,
 623 and (C-F) membrane bound *MUC1*, *MUC3*, *MUC4* and *MUC17* mRNA
 624 expression was measured by qPCR, with *GAPDH* as the internal control.
 625 Results were shown as mean of $\pm$ SEM from five independent experiments. *,

626 ***, *** $p < 0.05$, 0.01 and 0.001 compared to PBS control. One-way ANOVA
627 post Dunnet's test.

628

629

630 Fig. 4. Effects of 24 h DON incubation without or with EIEC post-infection (1
631 h) on mucin (MUC) protein production as measured by WGA assay. Results
632 were shown as mean of $\pm$ SEM from six independent experiments. * $p < 0.05$
633 compared to PBS control. One-way ANOVA post Dunn's test.

634

635 Fig. 5. Effects of 24 h DON incubation without or with EIEC post-infection (1
636 h) on cytokine and chemokine gene expression. (A-E) *IL1B*, *IL6*, *IL8*, *TNFA*
637 and *CCL2* mRNA expression was measured by qPCR, with *GAPDH* as the
638 internal control. Results were shown as mean of $\pm$ SEM from five independent
639 experiments. *, ***, **** $p < 0.05$, 0.001 and 0.0001 compared to PBS control.
640 One-way ANOVA post Dunn's test.

641

642 Fig. 6. Effects of 24 h DON incubation without or with EIEC post-infection (1
643 h) on toll-like receptor (TLR) and *MYD88* gene expression. (A-E) *TLR1*, *TLR2*,
644 *TLR5*, *TLR6* and *MYD88* mRNA expression was measured by qPCR, with
645 *GAPDH* as the internal control. Results were shown as mean of $\pm$ SEM from
646 five independent experiments. *, ** $p < 0.05$, 0.01 compared to PBS control.
647 One-way ANOVA post Dunn's test.

648

649 Fig. 7. Effects of 24 h DON incubation without or with EIEC post-infection (1
650 h) on NF- κ B and MAPK signalling pathways. (A) *RELA* mRNA expression was

651 measured by qPCR, with *GAPDH* as the internal control. Results were shown
 652 as mean of $\pm$ SEM from six independent experiments. (B) NF- κ B p65 protein
 653 expression was measured by Western blotting, with *GAPDH* as the internal
 654 control. Representative photos of western blotting of NF- κ B p65 and *GAPDH*.
 655 Quantification of Western blot compared to PBS control from three
 656 independent experiments. Inset shows group means. (C) Protein samples
 657 were also analysed by Western blot with phospho-p38, JNK and ERK
 658 antibodies. The total MAPK levels were used as an internal control.
 659 Representative photos of western blotting of MAPKs and *GAPDH*. Results
 660 were shown as mean of $\pm$ SEM from four independent experiments. *, ***, ****
 661 $p < 0.05$, 0.001 and 0.0001 compared to PBS control. One-way ANOVA post
 662 Dunn's test.

663

664 Fig. 8. A summary of the proposed mechanisms of host defence responses
 665 against DON and EIEC co-exposures. Upon the exposure to DON and EIEC,
 666 intestinal epithelial cells are able to express and produce important mediators
 667 of inflammation such as cytokines and modulate other signal molecules like
 668 TLRs that are important for host defence and bacterial recognition. The
 669 augmented mucin production and inflammatory stimulation might be a
 670 consequence of activation of NF- κ B signalling pathway. Infection of DON pre-
 671 treated cells with EIEC inhibited MAPK signalling pathways which might help
 672 protecting intestinal epithelial cells from further damages caused by bacterial
 673 infection.

674

675 Table 1. Human specific primer sequences for qPCR.

676

677

678

679

680 **References**

681

682 Adesso, S., A. Quaroni, A. Popolo, L. Severino and S. Marzocco (2017). "The
683 food contaminants nivalenol and deoxynivalenol induce inflammation in
684 intestinal epithelial cells by regulating reactive oxygen species release."
685 Nutrients **9**(12): 1343.

686 Aggarwal, B. B., Y. Takada, S. Shishodia, A. M. Gutierrez, O. V. Oommen, H.
687 Ichikawa, Y. Baba and A. Kumar (2004). "Nuclear transcription factor NF-
688 kappa B: role in biology and medicine." Indian J Exp Biol.

689 Akira, S., S. Uematsu and O. Takeuchi (2006). "Pathogen recognition and
690 innate immunity." Cell **124**(4): 783-801.

691 Antonissen, G., F. Van Immerseel, F. Pasmans, R. Ducatelle, G. P. J.
692 Janssens, S. De Baere, K. C. Mountzouris, S. Su, E. A. Wong, B. De
693 Meulenaer, M. Verlinden, M. Devreese, F. Haesebrouck, B. Novak, I. Dohnal,
694 A. Martel and S. Croubels (2015). "Mycotoxins deoxynivalenol and fumonisins
695 alter the extrinsic component of intestinal barrier in broiler chickens." J Agric
696 Food Chem **63**(50): 10846-10855.

697 Arce, C., M. Ramírez-Boo, C. Lucena and J. Garrido (2010). "Innate immune
698 activation of swine intestinal epithelial cell lines (IPEC-J2 and IPI-2I) in
699 response to LPS from *Salmonella typhimurium*." Comp Immunol Microbiol
700 Infect Dis **33**: 161-174.

701 Boudeau, J., A.-L. Glasser, E. Masseret, B. Joly and A. Darfeuille-Michaud
702 (1999). "Invasive ability of an *Escherichia coli* strain isolated from the ileal
703 mucosa of a patient with Crohn's disease." Infect Immun **67**(9): 4499-4509.

- 704 Cheng, Y.-H., C.-F. Weng, B.-J. Chen and M.-H. Chang (2006). "Toxicity of
705 different *Fusarium* mycotoxins on growth performance, immune responses
706 and efficacy of a mycotoxin degrading enzyme in pigs." Anim Res **55**(6): 579-
707 590.
- 708 Croxen, M. A., R. J. Law, R. Scholz, K. M. Keeney, M. Wlodarska and B. B.
709 Finlay (2013). "Recent advances in understanding enteric pathogenic
710 *Escherichia coli*." Clin Microbiol Rev **26**(4): 822-880.
- 711 Dąbek, J., A. Kułach and Z. Gąsior (2010). "Nuclear factor kappa-light-chain-
712 enhancer of activated B cells (NF-κB): a new potential therapeutic target in
713 atherosclerosis?" Pharmacol Rep **62**(5): 778-783.
- 714 Del Regno, M., S. Adesso, A. Popolo, A. Quaroni, G. Autore, L. Severino and
715 S. Marzocco (2015). "Nivalenol induces oxidative stress and increases
716 deoxynivalenol pro-oxidant effect in intestinal epithelial cells." Toxicol Appl
717 Pharm **285**(2): 118-127.
- 718 Eaves-Pyles, T., C. A. Allen, J. Taormina, A. Swidsinski, C. B. Tutt, G. Eric
719 Jezek, M. Islas-Islas and A. G. Torres (2008). "*Escherichia coli* isolated from a
720 Crohn's disease patient adheres, invades, and induces inflammatory
721 responses in polarized intestinal epithelial cells." Int J Med Microbiol **298**(5):
722 397-409.
- 723 Fukata, T., K. Sasai, E. Baba and A. Arakawa (1996). "Effect of ochratoxin A
724 on *Salmonella typhimurium*-challenged layer chickens." Avian Dis: 924-926.
- 725 Ganan, M., M. Collins, R. Rastall, A. Hotchkiss, H. Chau, A. Carrascosa and
726 A. Martinez-Rodriguez (2010). "Inhibition by pectic oligosaccharides of the
727 invasion of undifferentiated and differentiated Caco-2 cells by *Campylobacter*
728 *jejuni*." Int J Food Microbiol **137**(2-3): 181-185.

- 729 Garg, M., J. A. Potter and V. M. Abrahams (2013). "Identification of
730 microRNAs that regulate TLR2-mediated trophoblast apoptosis and inhibition
731 of IL-6 mRNA." PLOS One **8**(10): e77249.

- 732 Ghareeb, K., W. A. Awad, C. Soodoi, S. Sasgary, A. Strasser and J. Böhm
733 (2013). "Effects of feed contaminant deoxynivalenol on plasma cytokines and
734 mRNA expression of immune genes in the intestine of broiler chickens."
735 PLOS One **8**(8): e71492.

- 736 Hattrup, C. L. and S. J. Gendler (2008). "Structure and function of the cell
737 surface (tethered) mucins." Annu Rev Physiol **70**: 431-457.

- 738 Hayden, M. S. and S. Ghosh (2004). "Signaling to NF-κB." Genes Dev **18**(18):
739 2195-2224.

- 740 Heazlewood, C. K., M. C. Cook, R. Eri, G. R. Price, S. B. Tauro, D. Taupin, D.
741 J. Thornton, C. W. Png, T. L. Crockford, R. J. Cornall, R. Adams, M. Kato, K.
742 A. Nelms, N. A. Hong, T. H. J. Florin, C. C. Goodnow and M. A. McGuckin
743 (2008). "Aberrant mucin assembly in mice causes endoplasmic reticulum
744 stress and spontaneous inflammation resembling ulcerative colitis." PLOS
745 Med **5**(3): e54.

- 746 Ho, S. B., L. A. Dvorak, R. E. Moor, A. C. Jacobson, M. R. Frey, J. Corredor,
747 D. B. Polk and L. L. Shekels (2006). "Cysteine-rich domains of muc3 intestinal
748 mucin promote cell migration, inhibit apoptosis, and accelerate wound
749 healing." Gastroenterology **131**(5): 1501-1517.

- 750 Ho, S. B., G. A. Niehans, C. Lyftogt, P. S. Yan, D. L. Cherwitz, E. T. Gum, R.
751 Dahiya and Y. S. Kim (1993). "Heterogeneity of mucin gene expression in
752 normal and neoplastic tissues." Cancer Res **53**(3): 641-651.

- 753 Huang, B., X.-D. Yang, A. Lamb and L.-F. Chen (2010). "Posttranslational
754 modifications of NF-kappaB: another layer of regulation for NF-kappaB
755 signaling pathway." Cell Signal **22**(9): 1282-1290.

- 756 Ishiyama, M., Y. Miyazono, K. Sasamoto, Y. Ohkura and K. Ueno (1997). "A
757 highly water-soluble disulfonated tetrazolium salt as a chromogenic indicator
758 for NADH as well as cell viability." Talanta **44**(7): 1299-1305.

- 759 Islam, M. R., Y. S. Roh, J. Kim, C. W. Lim and B. Kim (2013). "Differential
760 immune modulation by deoxynivalenol (vomitoxin) in mice." Toxicol Lett
761 **221**(2): 152-163.

- 762 Jung, H., L. Eckmann, S. Yang, A. Panja, J. Fierer, E. Morzycka-Wroblewska
763 and M. Kagnoff (1995). "A distinct array of proinflammatory cytokines is
764 expressed in human colon epithelial cells in response to bacterial invasion." J
765 Clin Invest **95**: 55-65.

- 766 Kalaiselvi, P., K. Rajashree, L. B. Priya and V. V. Padma (2013).
767 "Cytoprotective effect of epigallocatechin-3-gallate against deoxynivalenol-
768 induced toxicity through anti-oxidative and anti-inflammatory mechanisms in
769 HT-29 cells." Food Chem Toxicol **56**: 110-118.

- 770 Karin, M., T. Lawrence and V. Nizet (2006). "Innate immunity gone awry:
771 linking microbial infections to chronic inflammation and cancer." Cell **124**(4):
772 823-835.

- 773 Khodaii, Z., S. M. H. Ghaderian and M. M. Natanzi (2017). "Probiotic bacteria
774 and their supernatants protect enterocyte cell lines from enteroinvasive
775 *Escherichia coli* (EIEC) invasion." Int J Mol Cell Med **6**(3): 183.

- 776 Kim, Y. S. and S. B. Ho (2010). "Intestinal goblet cells and mucins in health
777 and disease: recent insights and progress." Curr Gastroenterol Rep **12**(5):
778 319-330.

- 779 Krishnaswamy, R., S. N. Devaraj and V. V. Padma (2010). "Lutein protects
780 HT-29 cells against deoxynivalenol-induced oxidative stress and apoptosis:
781 prevention of NF-κB nuclear localization and down regulation of NF-κB and
782 cyclo-oxygenase-2 expression." Free Radic Biol Med **49**(1): 50-60.

783 Larsson, J. M. H., H. Karlsson, J. G. Crespo, M. E. Johansson, L. Eklund, H.
784 Sjövall and G. C. Hansson (2011). "Altered O-glycosylation profile of MUC2
785 mucin occurs in active ulcerative colitis and is associated with increased
786 inflammation." Inflamm Bowel Dis **17**(11): 2299-2307.

787 Liévin-Le Moal, V. and A. L. Servin (2006). "The front line of enteric host
788 defense against unwelcome intrusion of harmful microorganisms: mucins,
789 antimicrobial peptides, and microbiota." Clin Microbiol Rev **19**(2): 315-337.

790 Lindén, S. K., T. H. J. Florin and M. A. McGuckin (2008). "Mucin dynamics in
791 intestinal bacterial infection." PLOS One **3**(12): e3952.

792 Liu, Z., Y. Ma, M. P. Moyer, P. Zhang, C. Shi and H. Qin (2012). "Involvement
793 of the mannose receptor and p38 mitogen-activated protein kinase signaling
794 pathway of the microdomain of the integral membrane protein after
795 enteropathogenic *Escherichia coli* infection." Infect Immun **80**(4): 1343-1350.

796 Livak, K. J. and T. D. Schmittgen (2001). "Analysis of relative gene
797 expression data using real-time quantitative PCR and the 2- $\Delta\Delta$ CT method."
798 Methods **25**(4): 402-408.

799 Longman, R. J., R. Poulsom, A. P. Corfield, B. F. Warren, N. A. Wright and M.
800 G. Thomas (2006). "Alterations in the composition of the supramucosal
801 defense barrier in relation to disease severity of ulcerative colitis." J
802 Histochem Cytochem **54**(12): 1335-1348.

803 Maciorowski, K. G., P. Herrera, F. T. Jones, S. D. Pillai and S. C. Ricke
804 (2007). "Effects on poultry and livestock of feed contamination with bacteria
805 and fungi." Anim Feed Sci Tech **133**(1): 109-136.

806 McAuley, J. L., S. K. Linden, C. W. Png, R. M. King, H. L. Pennington, S. J.
807 Gendler, T. H. Florin, G. R. Hill, V. Korolik and M. A. McGuckin (2007).
808 "MUC1 cell surface mucin is a critical element of the mucosal barrier to
809 infection." J Clin Invest **117**(8): 2313-2324.

810 Moehle, C., N. Ackermann, T. Langmann, C. Aslanidis, A. Kel, O. Kel-
811 Margoulis, A. Schmitz-Madry, A. Zahn, W. Stremmel and G. Schmitz (2006).
812 "Aberrant intestinal expression and allelic variants of mucin genes associated
813 with inflammatory bowel disease." J Mol Med **84**(12): 1055-1066.

814 Moniaux, N., F. Escande, N. Porchet, J. Aubert and S. Batra (2001).
815 "Structural organization and classification of the human mucin genes." Front
816 Biosci **6**: D1192-1206.

817 Moon, Y. and J. Pestka (2002). "Vomitoxin-induced cyclooxygenase-2 gene
818 expression in macrophages mediated by activation of ERK and p38 but not
819 JNK mitogen-activated protein kinases." Toxicol Sci **69**: 373-382.

820 Moon, Y. and J. Pestka (2003). "Cyclooxygenase-2 mediates interleukin-6
821 upregulation by vomitoxin (deoxynivalenol) *in vitro* and *in vivo*." Toxicol Appl
822 Pharm **187**: 80-88.

823 Nolan, T., R. E. Hands and S. A. Bustin (2006). "Quantification of mRNA
824 using real-time RT-PCR." Nat Protocols **1**(3): 1559-1582.

825 Oswald, I., C. Desautels, J. Laffitte, S. Fournout, S. Peres, M. Odin, P. Le
826 Bars, J. Le Bars and J. Fairbrother (2003). "Mycotoxin fumonisin B1 increases
827 intestinal colonization by pathogenic *Escherichia coli* in pigs." Appl Environ
828 Microbiol **69**: 5870-5874.

829 Pestka, J., H. Zhou, Y. Moon and Y. Chung (2004). "Cellular and molecular
830 mechanisms for immune modulation by deoxynivalenol and other
831 trichothecenes: unraveling a paradox." Toxicol Lett **153**: 61-73.

832 Pinton, P., F. Graziani, A. Pujol, C. Nicoletti, O. Paris, P. Ernouf, E. Di
833 Pasquale, J. Perrier, I. P. Oswald and M. Maresca (2015). "Deoxynivalenol
834 inhibits the expression by goblet cells of intestinal mucins through a PKR and
835 MAP kinase dependent repression of the resistin-like molecule β ." Mol Nutr
836 Food Res **59**: 1076-1087.

- 837 Reis, C. A., L. David, P. Correa, F. Carneiro, C. de Bolós, E. Garcia, U.
838 Mandel, H. Clausen and M. Sobrinho-Simões (1999). "Intestinal metaplasia of
839 human stomach displays distinct patterns of mucin (MUC1, MUC2, MUC5AC,
840 and MUC6) expression." Cancer Res **59**(5): 1003-1007.
- 841 Resta-Lenert, S. and K. E. Barrett (2003). "Live probiotics protect intestinal
842 epithelial cells from the effects of infection with enteroinvasive *Escherichia coli*
843 (EIEC)." Gut **52**(7): 988-997.
- 844 Resta-Lenert, S., S. Das, S. K. Batra and S. B. Ho (2011). "Muc17 protects
845 intestinal epithelial cells from enteroinvasive *E. coli* infection by promoting
846 epithelial barrier integrity." Am J Physiol- Gastrointest Liver Physiol **300**(6):
847 G1144-G1155.
- 848 Schneider, C. A., W. S. Rasband and K. W. Eliceiri (2012). "NIH Image to
849 ImageJ: 25 years of image analysis." Nat Methods **9**: 671-675.
- 850 Seeboth, J., R. Solinhac, I. P. Oswald and L. Guzylack-Piriou (2012). "The
851 fungal T-2 toxin alters the activation of primary macrophages induced by TLR-
852 agonists resulting in a decrease of the inflammatory response in the pig." Vet
853 Res **43**(1): 35.
- 854 Sergent, T., M. Parys, S. Garsou, L. Pussemier, Y.-J. Schneider and Y.
855 Larondelle (2006). "Deoxynivalenol transport across human intestinal Caco-2
856 cells and its effects on cellular metabolism at realistic intestinal
857 concentrations." Toxicol Lett **164**(2): 167-176.
- 858 Snyder, J. D. and A. Walker (1987). "Structure and function of intestinal
859 mucin: developmental aspects." Int Arch Allergy Immunol **82**(3-4): 351-356.
- 860 Sobrova, P., V. Adam, A. Vasatkova, M. Beklova, L. Zeman and R. Kizek
861 (2010). "Deoxynivalenol and its toxicity." Interdiscip Toxicol **3**(3): 94-99.

- 862 Stoev, S., D. Goundasheva, T. Mirtcheva and P. Mantle (2000). "Susceptibility
863 to secondary bacterial infections in growing pigs as an early response in
864 ochratoxicosis." Exp Toxicol Pathol **52**(4): 287-296.

- 865 Tai, J. H. and J. J. Pestka (1988). "Impaired murine resistance to *Salmonella*
866 *typhimurium* following oral exposure to the trichothecene T-2 toxin." Food
867 Chem Toxicol **26**(8): 691-698.

- 868 Takanashi, N., Y. Tomosada, J. Villena, K. Murata, T. Takahashi, E. Chiba, M.
869 Tohno, T. Shimazu, H. Aso, Y. Suda, S. Ikegami, H. Itoh, Y. Kawai, T. Saito,
870 S. Alvarez and H. Kitazawa (2013) "Advanced application of bovine intestinal
871 epithelial cell line for evaluating regulatory effect of lactobacilli against heat-
872 killed enterotoxigenic *Escherichia coli*-mediated inflammation." BMC Microbiol
873 **13**, 54 DOI: 10.1186/1471-2180-13-54.

- 874 Taranu, I., D. E. Marin, G. C. Pistol, M. Motiu and D. Pelinescu (2015).
875 "Induction of pro-inflammatory gene expression by *Escherichia coli* and
876 mycotoxin zearalenone contamination and protection by a *Lactobacillus*
877 mixture in porcine IPEC-1 cells." Toxicon **97**: 53-63.

- 878 Torres, A. G. and J. B. Kaper (2003). "Multiple elements controlling
879 adherence of enterohemorrhagic *Escherichia coli* O157: H7 to HeLa cells."
880 Infect Immun **71**(9): 4985-4995.

- 881 Underhill, D. M. and A. Ozinsky (2002). "Toll-like receptors: key mediators of
882 microbe detection." Curr Opin Immunol **14**(1): 103-110.

- 883 Van De Walle, J., A. During, N. Piront, O. Toussaint, Y.-J. Schneider and Y.
884 Larondelle (2010). "Physio-pathological parameters affect the activation of
885 inflammatory pathways by deoxynivalenol in Caco-2 cells." Toxicol In Vitro
886 **24**(7): 1890-1898.

887 Van De Walle, J., B. Romier, Y. Larondelle and Y. Schneider (2008).
888 "Influence of deoxynivalenol on NF-κB activation and IL-8 secretion in human
889 intestinal Caco-2 cells." Toxicol Lett **177**: 205-214.

890 Van De Walle, J., B. Romier, Y. Larondelle and Y.-J. Schneider (2008).
891 "Influence of deoxynivalenol on NF-κB activation and IL-8 secretion in human
892 intestinal Caco-2 cells." Toxicol Lett **177**(3): 205-214.

893 Vandenbroucke, V., S. Croubels, A. Martel, E. Verbrugghe, J. Goossens, K.
894 Van Deun, F. Boyen, A. Thompson, N. Shearer, P. De Backer, F.
895 Haesebrouck and F. Pasmans (2011). "The mycotoxin deoxynivalenol
896 potentiates intestinal inflammation by *Salmonella Typhimurium* in porcine ileal
897 loops." PLOS One **6**(8): e23871.

898 Vieira, M. A. M., T. A. T. Gomes, A. J. P. Ferreira, T. Knöbl, A. L. Servin and
899 V. Liévin-Le Moal (2010). "Two atypical enteropathogenic *Escherichia coli*
900 strains induce the production of secreted and membrane-bound mucins to
901 benefit their own growth at the apical surface of human mucin-secreting
902 intestinal HT29-MTX cells." Infect Immun **78**(3): 927-938.

903 Wan, L.-Y. M., K. J. Allen, P. C. Turner and H. El-Nezami (2014). "Modulation
904 of mucin mRNA (MUC5AC and MUC5B) expression and protein production
905 and secretion in Caco-2/HT29-MTX co-cultures following exposure to
906 individual and combined *Fusarium* mycotoxins." Toxicol Sci **139**(1): 83-98.

907 Wan, L.-Y. M., C.-S. J. Woo, P. C. Turner, J. M.-F. Wan and H. El-Nezami
908 (2013). "Individual and combined effects of *Fusarium* toxins on the mRNA
909 expression of pro-inflammatory cytokines in swine jejunal epithelial cells."
910 Toxicol Lett **220**(3): 238-246.


911 Wang, J. H., Y. J. Zhou, P. He and B. Y. Chen (2007). "Roles of mitogen-
912 activated protein kinase pathways during *Escherichia coli*-induced apoptosis
913 in U937 cells." Apoptosis **12**(2): 375-385.

914 Xue, Y., H. Zhang, H. Wang, J. Hu, M. Du and M.-J. Zhu (2014). "Host
915 inflammatory response inhibits *Escherichia coli* O157:H7 adhesion to gut
916 epithelium through augmentation of mucin expression." Infect Immun **82**(5):
917 1921-1930.


918 Zhuang, X., Z. Chen, C. He, L. Wang, R. Zhou, D. Yan and B. Ge (2017).
919 "Modulation of host signaling in the inflammatory response by
920 enteropathogenic *Escherichia coli* virulence proteins." Cell Mol Immunol
921 **14**(3): 237-244.

922


A




B



A




B




Secretory mucins

A




B




Membrane bounded mucins


C




D




E




F




Total mucin glycoprotein
(Compared to PBS)




A




B




C




D




E




A




B




C



D




E



NFkB pathways

A




B




MAPK pathways

C



D






Table 1. Human specific primer sequences for qPCR

Gene name	Abbreviated name	Product length (bp)	Forward primer sequence (5'-3')	Reverse primer sequence (5'-3')	Accession Number	Reference
Mucin 1	MUC1	105	GTGGTGGTACAATTGACTCTGG	GTTATATCGAGAGGCTGCTTCC	NM_001204294.1	(Sperandio et al., 2013)
Mucin 3	MUC3	113	CTGCAACTACCAGCACTTCTTC	TATAGTTCCTGGACAGGGTGTG	NM_005960.2	(Sperandio et al., 2013)
Mucin 4	MUC4	113	AGGCTACCTCAAGACTCACCTC	TCATTCTCCTTGAAGAATCCTG	NM_018406.7	(Sperandio et al., 2013)
Mucin 5AC	MUC5AC	131	CTCCTACCAATGCTCTGTA	GTTGCAGAAGCAGGTTTG	NM_001304359.2	(Wan et al., 2014)
Mucin 5B	MUC5B	154	GACAGAGACGACAATGAG	CCTGATGTTTTCAAAAGTTTC	NM_002458.3	(Wan et al., 2014)
Mucin 17	MUC17	122	GTTTCAACACCACTGGCACC	CTGGTCCCGGTACTCCACTA	NM_001040105.1	NM_001040105.1
Interleukin-1 β	IL1B	138	TGGAGCAACAAGTGGTGTTT	GCTGTAGAGTGGGCTTATCATC	NM_000576.2	(Tian et al., 2016)
Interleukin-6	IL6	100	TGAAAGCAGCAAAGAGGCACT	GCAAGTCTCCTCATTGAATCCAG	NM_000600.5	(Tian et al., 2016)
Interleukin-8	IL8	98	CTGATTTCTGCAGCTCTGTG	GGGTGGAAAGGTTTGGAGTATG	NM_000584.4	(Kina et al., 2009)
Tumor necrosis factor- α	TNFA	93	CTGCTGCACTTTGGAGTGAT	AGATGATCTGACTGCCTGGG	NM_000594.4	(Chanput et al., 2010)
Monocyte chemoattractant protein 1	CCL3	171	CCCCAGTCACCTGCTGTTAT	TGGAATCCTGAACCCACTTC	NM_002982.4	NM_002982.3
Toll-like receptor-1	TLR1	135	GCCCAAGGAAAAGAGCAAAC	AAGCAGCAATATCAACAGGAG	NM_003263.4	(Lee et al., 2014)

Toll-like receptor-2	TLR2	125	TCTCCCATTTCCGTCTTTTT	GGTCTTGGTGTTTCATTATCTTC	NM_001318796.1	(Lee et al., 2014)
Toll-like receptor-4	TLR4	213	GAAGCTGGTGGCTGTGGA	GATGTAGAACCCGCAAG	NM_138554.5	(Lee et al., 2014)
Toll-like receptor-5	TLR5	149	TTGCTCAAACACCTGGACAC	CTGCTCACAAGACAAACGAT	NM_003268.6	(Lee et al., 2014)
Toll-like receptor-6	TLR6	109	GTGCCATTACGAACTCTA	TTGTTGGGAATGCTGTT	NM_006068.4	(Lee et al., 2014)
Myeloid differentiation primary response 88	MYD88	143	GCAGAGCAAGGAATGTGACTTC	AGTCGCAGACAGTGATGAACCT	NM_001365877.1	(Tian et al., 2016)
RELA proto-oncogene, NF-kB subunit	RELA	112	TCTGCTTCCAGGTGACAGTG	ATCTTGAGCTCGGCAGTGTT	NM_021975.4	(Garg, Potter, and Abrahams, 2013)
Glyceraldehyde 3- phosphate dehydrogenase	GAPDH	159	CATGTTCGTCATGGGGTGAACCA	AGTGATGGCATGGACTGTGGTCA T	NM_002046.7	(Luo et al., 2017)